# 1 WHOLE GENOME SEQUENCING ANALYSIS OF BODY MASS INDEX IDENTIFIES NOVEL AFRICAN 2 ANCESTRY-SPECIFIC RISK ALLELE

3

### 4 **AUTHORS**

Xinruo Zhang<sup>1</sup>\*, Jennifer A. Brody<sup>2</sup>\*, Mariaelisa Graff<sup>1</sup>\*, Heather M. Highland<sup>1</sup>\*, Nathalie Chami<sup>3</sup>\*, 5 Hanfei Xu<sup>4</sup>, Zhe Wang<sup>3</sup>, Kendra Ferrier<sup>5</sup>, Geetha Chittoor<sup>6</sup>, Navya S. Josyula<sup>6</sup>, Xihao Li<sup>7</sup>, Zilin Li<sup>8</sup>, 6 Matthew A. Allison<sup>9</sup>, Diane M. Becker<sup>10,†</sup>, Lawrence F. Bielak<sup>11</sup>, Joshua C. Bis<sup>2</sup>, Meher Preethi 7 Boorgula<sup>12</sup>, Donald W. Bowden<sup>13</sup>, Jai G. Broome<sup>14,15</sup>, Erin J. Buth<sup>14</sup>, Christopher S. Carlson<sup>16</sup>, Kyong-Mi 8 Chang<sup>17,18</sup>, Sameer Chavan<sup>12</sup>, Yen-Feng Chiu<sup>19</sup>, Lee-Ming Chuang<sup>20</sup>, Matthew P. Conomos<sup>14</sup>, Dawn L. 9 DeMeo<sup>21</sup>, Margaret Du<sup>22</sup>, Ravindranath Duggirala<sup>23</sup>, Celeste Eng<sup>24</sup>, Alison E. Fohner<sup>25</sup>, Barry I. 10 Freedman<sup>26</sup>, Melanie E. Garrett<sup>27</sup>, Xiuqing Guo<sup>28</sup>, Chris Haiman<sup>29</sup>, Benjamin D. Heavner<sup>14</sup>, Bertha 11 Hidalgo<sup>30</sup>, James E. Hixson<sup>31</sup>, Yuk-Lam Ho<sup>32</sup>, Brian D. Hobbs<sup>21,33</sup>, Donglei Hu<sup>24</sup>, Qin Hui<sup>34,35</sup>, Chii-Min 12 Hwu<sup>36</sup>, Rebecca D. Jackson<sup>37,†</sup>, Deepti Jain<sup>14</sup>, Rita R. Kalyani<sup>38</sup>, Sharon L.R. Kardia<sup>11</sup>, Tanika N. Kelly<sup>39</sup>, 13 Ethan M. Lange<sup>5</sup>, Michael LeNoir<sup>40</sup>, Changwei Li<sup>39</sup>, Loic Le. Marchand<sup>41</sup>, Merry-Lynn N. McDonald<sup>42</sup>, 14 Caitlin P. McHugh<sup>14</sup>, Alanna C. Morrison<sup>31</sup>, Take Naseri<sup>43</sup>, NHLBI Trans-Omics for Precision Medicine 15 (TOPMed) Consortium<sup>44</sup>, Jeffrey O'Connell<sup>45</sup>, Christopher J. O'Donnell<sup>32,46</sup>, Nicholette D. Palmer<sup>13</sup>, 16 James S. Pankow<sup>47</sup>, James A. Perry<sup>48</sup>, Ulrike Peters<sup>49</sup>, Michael H. Preuss<sup>3</sup>, D.C. Rao<sup>50</sup>, Elizabeth A. 17 Regan<sup>51</sup>, Sefuiva M. Reupena<sup>52</sup>, Dan M. Roden<sup>53</sup>, Jose Rodriguez-Santana<sup>54</sup>, Colleen M. Sitlani<sup>2</sup>, Jennifer 18 A. Smith<sup>11,55</sup>, Hemant K. Tiwari<sup>56</sup>, Ramachandran S. Vasan<sup>57</sup>, Zevuan Wang<sup>34</sup>, Daniel E. Weeks<sup>58,59</sup>, 19 Jennifer Wessel<sup>60,61,62</sup>, Kerri L. Wiggins<sup>2</sup>, Lynne R. Wilkens<sup>41</sup>, Peter W.F. Wilson<sup>35,63</sup>, Lisa R. Yanek<sup>10</sup>, 20 Zachary T. Yoneda<sup>64</sup>, Wei Zhao<sup>11,55</sup>, Sebastian Zöllner<sup>65</sup>, Donna K. Arnett<sup>66</sup>, Allison E. Ashley-Koch<sup>27</sup>, 21 Kathleen C. Barnes<sup>12</sup>, John Blangero<sup>67</sup>, Eric Boerwinkle<sup>31</sup>, Esteban G. Burchard<sup>68</sup>, April P. Carson<sup>69</sup>, 22 Daniel I. Chasman<sup>70,71</sup>, Yii-Der Ida Chen<sup>72</sup>, Joanne E. Curran<sup>73</sup>, Myriam Fornage<sup>74,31</sup>, Victor R. 23 Gordeuk<sup>75</sup>, Jiang He<sup>39</sup>, Susan R. Heckbert<sup>76,2</sup>, Lifang Hou<sup>77</sup>, Marguerite R. Irvin<sup>78</sup>, Charles Kooperberg<sup>16</sup>, 24 25 Ryan L. Minster<sup>58</sup>, Braxton D. Mitchell<sup>79</sup>, Mehdi Nouraie<sup>80</sup>, Bruce M. Psaty<sup>2,76,81</sup>, Laura M. Raffield<sup>82</sup>, Alexander P. Reiner<sup>76</sup>, Stephen S. Rich<sup>83</sup>, Jerome I. Rotter<sup>28</sup>, M. Benjamin Shoemaker<sup>64</sup>, Nicholas L. 26

- 27 Smith<sup>84,85,86</sup>, Kent D. Taylor<sup>28</sup>, Marilyn J. Telen<sup>87</sup>, Scott T. Weiss<sup>88</sup>, Yingze Zhang<sup>80</sup>, Nancy Heard-
- 28 Costa<sup>89</sup>, Yan V. Sun<sup>34,35</sup>, Xihong Lin<sup>7,90</sup>, L. Adrienne Cupples<sup>4,¥,†</sup>, Leslie A. Lange<sup>5,¥</sup>, Ching-Ti Liu<sup>4,¥</sup>,
- 29 Ruth J.F.  $Loos^{3,91,¥}$ , Kari E. North<sup>1,¥</sup>, Anne E. Justice<sup>6,¥</sup>

30

- 31 \* These authors contributed equally to this work.
- 32 <sup>¥</sup> These authors equally supervised this work.
- 33 <sup>†</sup> Published posthumously
- 34

# 35 AUTHOR INFORMATION

36

# 37 Affiliations

<sup>1</sup>Department of Epidemiology, Gillings School of Global Public Health, University of North

- 39 Carolina at Chapel Hill, Chapel Hill, NC, USA. <sup>2</sup>Cardiovascular Health Research Unit,
- 40 Department of Medicine, University of Washington, Seattle, WA, USA. <sup>3</sup>The Charles Bronfman
- 41 Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, NY,

42 USA. <sup>4</sup>Department of Biostatistics, School of Public Health, Boston University, Boston, MA,

43 USA. <sup>5</sup>Division of Biomedical Informatics and Personalized Medicine, School of Medicine

- 44 University of Colorado, Anschutz Medical Campus, Aurora, CO, USA. <sup>6</sup>Population Health
- 45 Sciences, Geisinger, Danville, PA, USA. <sup>7</sup>Department of Biostatistics, Harvard T.H. Chan

46 School of Public Health, Boston, MA, USA. <sup>8</sup>Biostatistics and Health Data Science, Indiana

- 47 University School of Medicine, Indianapolis, IN, USA. <sup>9</sup>Department of Family Medicine,
- 48 Division of Preventive Medicine, The University of California San Diego, La Jolla, CA, USA.
- 49 <sup>10</sup>Department of Medicine, General Internal Medicine, Johns Hopkins University School of
- 50 Medicine, Baltimore, MD, USA. <sup>11</sup>Department of Epidemiology, School of Public Health,
- 51 University of Michigan, Ann Arbor, MI, USA. <sup>12</sup>Department of Medicine, School of Medicine,

52	University of Colorado, Aurora, CO, USA. <sup>13</sup> Department of Biochemistry, Wake Forest School
53	of Medicine, Winston-Salem, NC, USA. <sup>14</sup> Department of Biostatistics, School of Public Health,
54	University of Washington, Seattle, WA, USA. <sup>15</sup> Department of Medicine, Division of Medical
55	Genetics, University of Washington, Seattle, WA, USA. <sup>16</sup> Division of Public Health Sciences,
56	Fred Hutchinson Cancer Research Center, Seattle, WA, USA. <sup>17</sup> The Corporal Michael J.
57	Crescenz VA Medical Center, Philadelphia, PA, USA. <sup>18</sup> University of Pennsylvania Perelman
58	School of Medicine, Philadelphia, PA, USA. <sup>19</sup> Institute of Population Health Sciences, National
59	Health Research Institutes, Taipei, Taiwan. <sup>20</sup> Department of Internal Medicine, Division of
60	Metabolism/Endocrinology, National Taiwan University Hospital, Taipei, Taiwan. <sup>21</sup> Department
61	of Medicine, Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard
62	Medical School, Boston, MA, USA. <sup>22</sup> Epidemiology & Biostatistics, Memorial Sloan Kettering
63	Cancer Center, New York, NY, USA. <sup>23</sup> Life Sciences, College of Arts and Sciences, Texas
64	A&M University-San Antonio, San Antonio, TX, USA. <sup>24</sup> Department of Medicine, Lung
65	Biology Center, University of California, San Francisco, San Francisco, CA, USA.
66	<sup>25</sup> Epidemiology, Institute of Public Health Genetics, School of Public Health, University of
67	Washington, Seattle, WA, USA. <sup>26</sup> Internal Medicine, Section on Nephrology, Wake Forest
68	School of Medicine, Winston-Salem, NC, USA. <sup>27</sup> Department of Medicine, Duke Molecular
69	Physiology Institute, Duke University Medical Center, Durham, NC, USA. <sup>28</sup> Department of
70	Pediatrics, Genomic Outcomes, The Institute for Translational Genomics and Population
71	Sciences, Department of Pediatrics, The Lundquist Institute for Biomedical Innovation at
72	Harbor-UCLA Medical Center, Torrance, CA, USA. <sup>29</sup> Preventive Medicine, Keck School of
73	Medicine, University of Southern California, Los Angeles, CA, USA. <sup>30</sup> Department of
74	Epidemiology, School of Public Health, University of Alabama at Birmingham School of Public

75	Health, Birmingham, AL, USA. <sup>31</sup> Department of Epidemiology, Human Genetics and
76	Environmental Sciences, School of Public Health, The University of Texas Health Science
77	Center at Houston, Houston, TX, USA. <sup>32</sup> Veterans Affairs Boston Healthcare System, Boston,
78	MA, USA. <sup>33</sup> Division of Pulmonary and Critical Care Medicine, Brigham and Women's
79	Hospital, Harvard Medical School, Boston, MA, USA. <sup>34</sup> Department of Epidemiology, Emory
80	University Rollins School of Public Health, Atlanta, GA, USA. <sup>35</sup> Atlanta VA Health Care
81	System, Decatur, GA, USA. <sup>36</sup> Department of Medicine, Division of Endocrinology and
82	Metabolism, Taipei Veterans General Hospital, Taipei, Taiwan, Taiwan. <sup>37</sup> Endocrinology, Ohio
83	State University, Columbus, OH, USA. <sup>38</sup> Department of Medicine, Endocrinology, Johns
84	Hopkins University School of Medicine, Baltimore, MD, USA. <sup>39</sup> Department of Epidemiology,
85	School of Public Health and Tropical Medicine, Tulane University, New Orleans, LA, USA.
86	<sup>40</sup> Department of Pediatrics, Bay Area Pediatrics, Oakland, CA, USA. <sup>41</sup> Epidemiology Program,
87	University of Hawaii Cancer Center, Honolulu, HI, USA. <sup>42</sup> Department of Medicine, Pulmonary,
88	Allergy and Critical Care, University of Alabama at Birmingham, Birmingham, AL, USA.
89	<sup>43</sup> Ministry of Health, Government of Samoa, Apia, Samoa. <sup>44</sup> A full list of study authors are
90	provided in the acknowledgements within the Supplementary Note. <sup>45</sup> Department of Medicine,
91	Program for Personalized and Genomic Medicine, University of Maryland, Baltimore, MD,
92	USA. <sup>46</sup> Department of Medicine, Brigham and Women's Hospital, Harvard Medical School,
93	Boston, MA, USA. <sup>47</sup> Division of Epidemiology and Community Health, School of Public
94	Health, University of Minnesota, Minneapolis, MN, USA. <sup>48</sup> Department of Medicine, School of
95	Medicine, University of Maryland, Baltimore, MD, USA. <sup>49</sup> Division of Public Health Sciences,
96	Fred Hutchinson Cancer Center, Seattle, WA, USA. <sup>50</sup> Division of Biostatistics, Washington
97	University in St. Louis, St. Louis, MO, USA. <sup>51</sup> Department of Medicine, Rheumatology,

98	National Jewish Health, Denver, CO, USA. 52Lutia I Puava Ae Mapu I Fagalele, Apia, Samoa.
99	<sup>53</sup> Medicine, Pharmacology, and Biomedical Informatics, Clinical Pharmacology and
100	Cardiovascular Medicine, Vanderbilt University Medical Center, Nashville, TN, USA. 54Centro
101	de Neumologia Pediatrica, San Juan, PR, USA. 55 Survey Research Center, Institute for Social
102	Research, University of Michigan, Ann Arbor, MI, USA. <sup>56</sup> Department of Biostatistics,
103	University of Alabama at Birmingham School of Public Health, Birmingham, AL, USA.
104	<sup>57</sup> Department of Medicine, School of Medicine, Boston University, Boston, MA, USA.
105	<sup>58</sup> Department of Human Genetics, School of Public Health, University of Pittsburgh, Pittsburgh,
106	PA, USA. <sup>59</sup> Department of Biostatistics, Graduate School of Public Health, University of
107	Pittsburgh, Pittsburgh, PA, USA. <sup>60</sup> Department of Epidemiology, Indiana University,
108	Indianapolis, IN, USA. <sup>61</sup> Department of Medicine, Indiana University, Indianapolis, IN, USA.
109	<sup>62</sup> Diabaetes Translational Research Center, Indiana University, Indianapolis, IN, USA.
110	<sup>63</sup> Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA.
111	<sup>64</sup> Department of Medicine, Cardiovascular Medicine, Vanderbilt University Medical Center,
112	Nashville, TN, USA. <sup>65</sup> Department of Biostatistics, Department of Psychiatry, University of
113	Michigan, Ann Arbor, MI, USA. <sup>66</sup> Department of Epidemiology, Arnold School of Public
114	Health, University of South Carolina, Columbia, SC, USA. <sup>67</sup> Human Genetics and South Texas
115	Diabetes and Obesity Institute, School of Medicine, University of Texas Rio Grande Valley,
116	Brownsville, TX, USA. <sup>68</sup> Bioengineering and Therapeutic Sciences and Medicine, Lung Biology
117	Center, University of California, San Francisco, San Francisco, CA, USA. <sup>69</sup> Department of
118	Medicine, University of Mississippi, Jackson, MI, USA. <sup>70</sup> Division of Preventive Medicine,
119	Brigham and Women's Hospital, Boston, MA, USA. <sup>71</sup> Harvard Medical School, Boston, MA,
120	USA. <sup>72</sup> Department of Medical Genetics, Genomic Outcomes, Lundquist Institute for

121	Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, CA, USA. <sup>73</sup> Department of
122	Human Genetics and South Texas Diabetes and Obesity Institute, School of Medicine,
123	University of Texas Rio Grande Valley, Brownsville, TX, USA. <sup>74</sup> Brown Foundation Institute of
124	Molecular Medicine, McGovern Medical School, University of Texas Health Science Center at
125	Houston, Houston, TX, USA. 75Department of Medicine, School of Medicine, University of
126	Illinois at Chicago, Chicago, IL, USA. <sup>76</sup> Department of Epidemiology, University of
127	Washington, Seattle, WA, USA. 77Northwestern University, Chicago, IL, USA. 78Department of
128	Epidemiology, University of Alabama at Birmingham School of Public Health, Birmingham,
129	AL, USA. <sup>79</sup> Department of Medicine, Division of Endocrinology, Diabetes and Nutrition,
130	University of Maryland, Baltimore, MD, USA. 80 Department of Medicine, School of Medicine,
131	University of Pittsburgh, Pittsburgh, PA, USA. <sup>81</sup> Department of Health Systems and Population
132	Health, University of Washington, Seattle, WA, USA. <sup>82</sup> Department of Genetics, University of
133	North Carolina at Chapel Hill, Chapel Hill, NC, USA. <sup>83</sup> Public Health Science, Center for Public
134	Health Genomics, University of Virginia, Charlottesville, VA, USA. <sup>84</sup> Department of
135	Epidemiology, School of Public Health, University of Washington, Seattle, WA, USA. <sup>85</sup> Kaiser
136	Permanente Washington Health Research Institute, Kaiser Permanente Washington, Seattle, WA,
137	USA. <sup>86</sup> Seattle Epidemiologic Research and Information Center, Office of Research and
138	Development, Department of Veterans Affairs, Seattle, WA, USA. 87Department of Medicine,
139	Hematology, Duke University Medical Center, Durham, NC, USA. 88Department of Medicine,
140	Channing Division of Network Medicine, Harvard Medical School, Boston, MA, USA.
141	<sup>89</sup> Framingham Heart Study, School of Medicine, Boston University Chobanian & Avedisian
142	School of Medicine, Boston, MA, USA. <sup>90</sup> Department of Statistics, Harvard University, Boston,

- 143 MA, USA. <sup>91</sup>Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health
- 144 and Medical Science, University of Copenhagen, Copenhagen, Denmark
- 145

#### 146 **Corresponding Authors**

- 147 Anne E. Justice: aejustice1@geisinger.edu; Xinruo Zhang: xinruo@email.unc.edu
- 148

# 149 Author Contributions

- 150 Conducted analyses or contributed to figures and tables: XZ, JAB, MG, NC, ZhW, KF, GC, NSJ, QH,
- 151 AEJ; Supervised analyses: YVS, LAC, LAL, CTL, RJFL, KEN, AEJ. Contributed to the design of the
- 152 current study: XZ, JAB, MG, HMH, NC, HX, LAC, LAL, CTL, RJFL, KEN, AEJ. Contributed to the
- 153 conception or design of the TOPMed program and its operations (including organization and policies of
- 154 TOPMed e.g., exec committee, working group conveners, NHLBI staff, etc.): NC, ZhW, DLD, BDHe,
- 155 JEH, SLRK, TNK, JSP, EAR, RSV, JW, DKA, KCB, JH, SRH, BMP, LMR, SSR, JIR, NLS, KDT, LAC,
- 156 CTL, RJFL, KEN, AEJ. Provided phenotypic data and/or biosamples: MG, NC, MAA, LFB, MPB, SC,
- 157 DLD, RD, XG, CHa, BH, JEH, YH, RDJ, SLRK, EML, LLM, TN, NDP, MHP, EAR, SMR, DMD,
- 158 RSV, DEW, JW, LRW, LRY, ZTY, DKA, JB, EGB, JEC, MF, JH, SRH, CK, RM, BMP, LMR, APR,
- 159 SSR, JIR, MBS, NLS, NH, LAC, LAL, RJFL, KEN, AEJ. Acquired WGS and/or other omics data: LFB,
- 160 DLD, RD, JEH, SLRK, JAS, RSV, JW, WZ, DKA, JB, EGB, JEC, MF, JH, SRH, CK, BMP, APR, SSR,
- 161 JIR, NLS, KDT, LAC, RJFL, KEN, AEJ. Created software, processed, and/or analyzed WGS or other
- 162 study data for data summaries in this paper: XZ, JAB, MG, HMH, NC, JCB, JGB, EJB, MPC, BDHe, CL,
- 163 CPM, KLW, AEJ. Drafted the manuscript and revised according to co-author suggestions: XZ, JAB, MG,
- 164 HMH, NC, KEN, AEJ. All authors critically reviewed the manuscript, suggested revisions as needed, and
- 165 approved the final version.
- 166

#### 167 Disclosures/Competing Interests

DLD received grants from Bayer and honoraria from Novartis. BDHo receives grant support from Bayer
and has received an honorarium from AstraZeneca for an educational lecture. CJO is employed by
Novartis Institute of Biomedical Research, Cambridge MA KCB is an employee of Tempus.
BMPs serve on the TOPMed Steering Committee. LMR is a consultant for the TOPMed Administrative
Coordinating Center (through Westat). XLin is a consultant of AbbVie Pharmaceuticals and Verily Life
Sciences.

174

# 175 ACKNOWLEDGEMENTS

176 This work was funded in part by National Institutes of Health (NIH) grants (R01 DK122503, T32

177 HL007055, T32 HL129982, R01 HL142825, I01-BX003362, U01 HL120393, R01 HL68959, U01

178 HL072507, K08 HL136928, R01 HL119443, R01 HL055673-18S1, R01 HL92301, R01 HL67348, R01

179 NS058700, R0 AR48797, R01 DK071891, R01 AG058921, F32 HL085989, U01 HL089897, U01

180 HL089856, R01 HL093093, R01 HL133040, I01 BX003340, I01 BX004821, U01 HL072524, R01

181 HL104135-04S1, U01 HL054472, U01 HL054473, U01 HL054495, U01 HL054509, R01 HL055673

182 with supplement -18S1, R01 HL104608, R01 AI132476, R01 AI114555, R01 HL104608-S1, U01

183 HL072507, P20 GM109036, KL2 TR002490 and T32 HL129982, P01 HL132825, R35 CA197449, P01

184 CA134294, U19 CA203654, R01 HL113338, U01 HG009088, R01 HL142302, R01 DK124097, R01

185 DK110113, R01 DK107786, X01 HL134588, R01 HG010297, U01 HG007416, R01 HL105756) and

186 contracts (HHSN268201800001I, HHSN268201500014C, ) American Diabetes Association (ADA) grant

187 #1-19-PDF-045, the General Clinical Research Center of the Wake Forest University School of Medicine

188 (M01 RR07122), and a pilot grant from the Claude Pepper Older Americans Independence Center of

189 Wake Forest University Health Sciences (P60 AG10484). A full list of study acknowledgements is

190 detailed in the **Supplementary Note**.

191

#### 193 ABSTRACT

194 Obesity is a major public health crisis associated with high mortality rates. Previous genome-wide 195 association studies (GWAS) investigating body mass index (BMI) have largely relied on imputed data 196 from European individuals. This study leveraged whole-genome sequencing (WGS) data from 88,873 197 participants from the Trans-Omics for Precision Medicine (TOPMed) Program, of which 51% were of non-European population groups. We discovered 18 BMI-associated signals ( $P < 5 \times 10^{-9}$ ). Notably, we 198 199 identified and replicated a novel low frequency single nucleotide polymorphism (SNP) in MTMR3 that 200 was common in individuals of African descent. Using a diverse study population, we further identified 201 two novel secondary signals in known BMI loci and pinpointed two likely causal variants in the POC5 202 and DMD loci. Our work demonstrates the benefits of combining WGS and diverse cohorts in expanding 203 current catalog of variants and genes confer risk for obesity, bringing us one step closer to personalized 204 medicine.

205

#### 206 INTRODUCTION

In 2015, approximately 12% of adults worldwide had obesity <sup>1</sup>, and four years later, the global obesity-related deaths amounted to five million, translating to an age-standardized mortality rate of 62.6 per 100,000 individuals in 2019 <sup>2</sup>. Previous genome-wide association studies (GWAS) have identified hundreds of loci associated with obesity-related traits, primarily with body mass index (BMI) – a practical and widely used proxy of overall adiposity. However, most of these genome-wide screens relied on metaanalyses of imputed data, predominantly from individuals of European ancestry <sup>3,4</sup>.

Despite making some advancements toward improving ancestral diversity in GWAS, ancestrystratified analyses and multi-ancestry analyses leveraged for discovery and fine-mapping are uncommon and largely underpowered by comparison. Furthermore, follow-up investigations for known BMI loci identified in European ancestry populations are insufficiently conducted to evaluate the generalizability of these loci. As such, the majority of BMI risk variants are common variants (minor allele frequency [MAF] > 5%) in primarily European ancestry populations, most of which exhibit small effect sizes. While

these index variants collectively explain less than 5% of the total phenotypic variation in BMI<sup>5</sup>, it is 219 220 estimated that as much as 1/5 of the phenotypic variance can be captured by common variants across the entire genome <sup>5</sup>, leaving low and rare variants (MAF  $\leq$  5%) with potentially large effects to be explored <sup>6</sup>. 221 222 Whole-genome sequencing (WGS) outperforms genotyping arrays in capturing low and rare 223 frequency variants, as demonstrated in a recent study where researchers revealed that the heritability of BMI estimated using WGS data was comparable to the pedigree-based estimates,  $h^2 \approx 0.40^{7}$ . Thus, the 224 225 discrepancy between phenotypic variance explained by genetic variations in GWAS compared to the 226 expected heritability may be due to the use of imputed genotypes rather than directly sequenced 227 variations. Causal variants or SNPs in known loci may not be represented on 1000 Genomes panels, or 228 not well imputed from reference data because of differences in linkage disequilibrium (LD) across 229 populations. To address this limitation, we conducted WGS association analyses to identify rare, low-230 frequency, and ancestry-specific genetic variants associated with BMI, using data from the Trans-Omics for Precision Medicine (TOPMed) Program<sup>8</sup>, which is the most racially and ethnically diverse WGS 231 program to date, as well as the Centers for Common Disease Genomics (CCDG) Program 9. 232 233 234 **METHODS** 235 236 **Study Population and Phenotype** 237 Our study population was racially, ethnically, geographically, and ancestrally diverse. We 238 analyzed a multi-population sample of 88,873 adults from 36 studies in the freeze 8 TOPMed and CCDG 239 programs (Figure 1, Supplementary Data 1). They belonged to 15 population groups, reflecting the way 240 participants self-identified in each study. For individuals who had unreported or non-specific population 241 memberships (e.g., "Multiple" or "Other"), we applied the Harmonized Ancestry and Race/Ethnicity (HARE) method <sup>10</sup> to infer their group memberships using genetic data. This imputation was applied to 242 243 8,015 participants (9% of the overall population), assigning each to one of the existing population groups.

244 In this way, our study population groups were defined based on a combination of self-reported identity

245	and the first	t nine geneti	c principal	l components	(PCs) (H	Figure 1.	, Supplementar	v Fig 1, and	I
					() (-			, _ <b></b> _ ,	

# 246 **Supplementary Data 1**).

247	The 15 population groups were labeled by their self-identified or primary inferred population
248	group (e.g., predominantly African ancestry/admixed African/Black were labeled as "African"). Sample
249	sizes for these groups ranged from 341 to over 43,000 as follows: African ( $N = 22,488$ ), Amish ( $N =$
250	1,106), Asian (N = 1,241), Barbadian (N = 248), Central American (N = 776), Costa Rican (N = 341),
251	Cuban (N = 2,128), Dominican (N = 2,046), European (N = 43,434), Han Chinese (N = 1,787), Mexican
252	(N = 4,265), Puerto Rican $(N = 4,991)$ , Samoan $(N = 1,274)$ , South American $(N = 695)$ , and Taiwanese
253	(N = 2,053). We refer to analyses involving all 15 population groups as multi-population analysis and
254	group-specific analyses by their primary population group.
255	Among the 88,873 participants, 53,109 (60%) were female and 45,439 (51%) were non-
256	European. The mean (SD) age of the participants was 53.5 (15.1) years. Additional descriptive tables of
257	the participants are presented in Supplementary Data 2 – 4. BMI was calculated by dividing weight in
258	kilograms by the square of height in meters. Participants were excluded from analyses if less than 18
259	years of age, had known pregnancy at the time of BMI measurement, had implausible BMI values (above
260	$100 \text{ kg/m}^2$ without corroborating evidence), or did not provide appropriate consent. The mean (SD) of
261	BMI varied by study, ranging from 23.4 (3.1) in GenSALT to 32.7 (6.8) in VAFAR (Supplementary
262	Data 2), and by population group, ranging from 23.4 (3.1) in Han Chinese to 33.7 (6.8) in Samoans
263	(Supplementary Data 3).
264	
265	TOPMed WGS

A detailed description of WGS methods has been reported previously <sup>11</sup>. Details regarding the laboratory methods, data processing, and quality control are described on the TOPMed website (https://www.nhlbiwgs.org/methods). Briefly, ~30X WGS was conducted using Illumina HiSeq X Ten instruments at six sequencing centers. At the Center for Statistical Genetics at University of Michigan, TOPMed sequence data were mapped to the GRCh38 human genome reference sequence in a manner

consistent with the joint CCDG/TOPMed functionally equivalent read mapping pipeline <sup>12</sup>. Joint
genotype calling on all samples in Freeze 8 used the GotCloud pipeline <sup>13</sup>. Variants were filtered using a
Support Vector Machine (SVM) implemented in the libsvm software package. Sample-level quality
assurance steps included concordance between annotated and genetic sex, between prior SNP array
genotyping and WGS-derived genotypes, and between observed and expected relatedness and pedigree
information from cleaned sequence data.

277

#### 278 **Common Variant Association Analysis**

We performed multi-population WGS association analysis of BMI using GENESIS<sup>14</sup> on the 279 Analysis Commons (http://analysiscommons.com)<sup>15</sup> computation platform. Analyses were performed 280 281 using linear mixed models (LMM). To improve power and control for false positives with a non-normal 282 phenotype distribution, we implemented a fully adjusted two-stage procedure for rank-normalization when fitting the null model <sup>16</sup>. The first model was fit by adjusting BMI for age, age squared, sex, study, 283 population group, ancestry-representative PCs generated using PC-AiR<sup>17</sup>, sequencing center, sequencing 284 phase and project. A 4<sup>th</sup> degree sparse empirical kinship matrix (KM) computed with PC-Relate <sup>18</sup> was 285 286 included to account for genetic relatedness among participants. We also allowed for heterogeneous 287 residual variances across sex by population group (e.g., female European), as it has previously been shown to improve control of genomic inflation<sup>19</sup>. Residuals from the first model were rank normal 288 289 transformed within population group and sex strata. The resulting transformed residuals were used to fit 290 the second stage null model allowing for heterogeneous variances by the population group and sex strata 291 and accounting for relatedness using the kinship matrix. Variants with a MAF of at least 0.5% were then 292 tested individually.

# Due to the large number of variants tested (N = 90,142,062) in the multi-population analysis, we adopted a significance threshold of $5 \times 10^{-9}$ as has been used previously <sup>20</sup>. Group-specific analyses were conducted in the two largest population groups, European and African.

#### 297 Replication Analyses

298 For the novel single-variant association identified in our discovery analyses, we requested 299 replication from five independent cohorts of similar race, ethnicity, and continental ancestry to our 300 discovery populations ( $N_{total} = 109,748$ ): Multiethnic Cohort (MEC)<sup>21</sup>, Million Veteran Program (MVP) <sup>22,23</sup>, BioMe BioBank Program <sup>24</sup>, UK Biobank (UKBB) <sup>25,26</sup>, and the REasons for Geographic And Racial 301 Differences in Stroke (REGARDS) study <sup>27</sup>. Phenotypes were developed and analyses were carried out 302 under the same protocol as outlined above. We subsequently conducted inverse variance weighted fixed 303 effects meta-analysis in METAL<sup>28</sup>, using study-specific summary results. Additional details on the parent 304 305 study design for each replication study are included in the **Supplementary Note**. 306

#### 307 Conditional Analysis

To identify loci harboring multiple independent signals, we performed stepwise conditional analyses on the most significant signal within 500kb of our index variant. The significance threshold for secondary signals was determined by Bonferroni correction for the number of variants across all regions tested,  $P = 5.96 \times 10^{-7}$  (P < 0.05/83,928 SNPs with MAF > 0.5% within 500kb of the 16 index SNPs). Variants passing the significance threshold after the first round were further conditioned on the top variant in the locus after the first round of conditioning, to identify potential third signals within each locus using the same threshold.

315 To determine whether association signals in known loci were independent of known signals, we performed conditional analyses using previously published index variants <sup>5,29-48</sup>. Specifically, we analyzed 316 317 all genome-wide significant variants that were not the previously reported index variants but located 318 within 500 kb of a known GWAS SNP. Given that these are potential new signals in regions known to 319 influence BMI, index variants were considered independent if the estimated effect ( $\beta$ ) value remained  $\geq$ 90% of the unconditioned  $\beta$  value and  $P < 6.25 \times 10^{-3}$  (0.05/8 loci tested). LDlink was used to calculate 320 321 pairwise LD between potentially independent signals in known loci and produce LD heatmaps using the 1000 Genomes Global reference panel<sup>49</sup>. 322

### 323

324	Rare Variant Aggregate Association Analysis
325	Rare variants with a MAF $\leq$ 1% were tested in aggregate by gene unit across studies in the multi-
326	population analysis. Variants were grouped into gene units in reference to GENCODE v28, including
327	both coding variants and variants falling within gene-associated non-coding elements. Coding variants
328	included high-confidence loss of function variants (Ensembl Variant Effect Predictor [VEP] LoF = HC),
329	missense variants (MetaSVM score $> 0$ ) and in-frame insertion/deletions or synonymous variants
330	(FATHNMM-XF coding score $> 0.5$ ). In addition to coding variants, we included variants falling within
331	the promoter of each transcript tested. Promoter regions were defined as falling in the 5 kb region 5' of
332	the transcript and also overlaying a FANTOM5 Cage Peak <sup>50</sup> . In order to identify regulatory elements
333	likely to be acting through the tested gene, we leveraged the GeneHancer database <sup>51</sup> . GeneHancer
334	identifies enhancer regions and associates them with the specific genes they are likely to regulate,
335	allowing us to aggregate regulatory regions by the likely target gene. GeneHancer regions were limited to
336	the top 50% scored regions and variants falling in these regulatory elements were further filtered to those
337	most likely to have a functional impact (FATHMM-MKL noncoding score $> 0.75$ ). Variants aggregated
338	to gene units were tested using variant set mixed model association tests (SMMAT) <sup>52</sup> . Variants were
339	weighted inversely to their MAF using a beta distribution density function with parameters 1 and 25.
340	Genes were considered significantly associated after Bonferroni correction for the number of genes
341	analyzed ( $P < 5 \times 10^{-7}$ ).

342

# 343 Fine-Mapping

In order to identify candidate functional variants underlying association regions, we performed fine-mapping analyses in our multi-population GWAS single variant association summary statistics, using the program PAINTOR <sup>53</sup> which integrates the association strength and genomic functional annotation. We used the annotation file from aggregate-based testing described above under "Rare Variant Aggregate Association Analysis" to identify deleterious coding variants, variants within GeneHancer regions, and

variants within gene promoter regions. We restricted this analysis to variants located within 100 kb of the locus index variants. We calculated LD using our analysis subset of the TOPMed data, assuming one causal variant per locus, unless evidence of independent secondary signals was identified, in which case we allowed for two causal variants per locus.

- 353
- 354 PheWAS

355 To identify potential novel phenotypic associations with newly discovered variants, we performed 356 a phenome-wide association (PheWAS) in the MyCode Community Health Initiative Study (MyCode), a hospital-based population study in central and northeastern Pennsylvania <sup>54</sup>, and in the Charles Bronfman 357 Institute for Personalized Medicine's BioMe BioBank Program (BioMe) located in New York City<sup>55</sup>; 358 359 both studies had genetic data linked to electronic health records (EHR). ICD-10-CM and ICD-9-CM 360 codes were mapped to unique PheCodes using the Phecode Map v1.2<sup>56</sup> from the EHR. Cases were 361 defined if individuals had two or more PheCodes on separate dates, while controls had zero instances of 362 the relevant PheCode. We performed association analyses on PheCodes with N  $\geq$  20 cases and 20 controls 363 using logistic regressions, adjusting for current age, sex (for non-sex-specific PheCodes), and the first 15 364 PCs calculated from genome-wide data, and assuming an additive genetic model using the PheWAS package <sup>57</sup> in R. Analyses were conducted in the overall population as well as in individuals of 365 genetically-informed African ancestry alone (as inferred from k-means clustering of the PCs <sup>58</sup>), given the 366 367 potential population-specific association of our novel locus. We restricted our analyses to unrelated individuals up to 2<sup>nd</sup> degree. Association analyses were conducted within each study, followed by inverse 368 variance weighted fixed effects meta-analysis in METAL<sup>28</sup>. PheCodes were deemed statistically 369 significant after Bonferroni correction for the number of PheCodes analyzed ( $P < 0.05/538 = 9.3 \times 10^{-5}$ ). 370

# 372 **RESULTS**

# 373 Single-variant Analyses

374	Among the 90 million SNPs included in the multi-population analysis, $86\%$ (N = 77,178,487)
375	were rare SNPs with a study-wide MAF of $0.5\% < MAF \le 1\%$ , and $6\%$ (N = 5,542,150) were low-
376	frequency ( $1\% < MAF \le 5\%$ ) SNPs. In the multi-population unconditional analysis, we identified 16 loci
377	that reached the prespecified genome-wide significance threshold of $P < 5 \times 10^{-9}$ ( <b>Table 1</b> , <b>Figure 2</b> ,
378	Supplementary Figs. $2 - 3$ ), including one low-frequency (MAF = 4%) and 15 common (MAF 14% –
379	50%) tag SNPs. In general, the low-frequency variant in our primary discovery showed a stronger effect
380	than the common variants, with an estimated effect 2.14 times larger than the average common variants
381	(0.078 vs. 0.037 on average). Of these 16 loci, 15 were in known BMI-associated regions, and one novel
382	locus was identified on chromosome 22 harboring a low-frequency index SNP near MTMR3
383	(rs111490516; MAF = 4%, $\beta$ = 0.078, SE = 0.013, $P$ = 4.52 × 10 <sup>-9</sup> ; <b>Table 1</b> ). The MAF of this <i>MTMR3</i>
384	locus varied widely across population groups, with the highest MAF observed in the African (13%) and
385	Barbadian (13%) population groups, while it ranged from 0% to 5% in other population groups
386	(Supplementary Data 5).
387	In the two population-specific analyses, 10 association signals reached genome-wide significance
388	(Supplementary Data 6, Supplementary Figs 4 – 7). Two of these signals were also detected in the
389	multi-population analysis. For two loci, SEC16B and FTO, each population-specific analysis revealed a
390	distinct lead variant compared to the multi-population analysis; however, they were in high LD with (R <sup>2</sup> =
391	0.95 and $R^2 = 1.00$ , according to TOP-LD <sup>59</sup> ; <b>Supplementary Data 6</b> ) and within 30 kb of the multi-
392	population lead SNPs. Notably, the novel locus in MTMR3 achieved significance exclusively in the
393	African group. While the most significant SNP in the African population group (rs73396827) differed
394	from that in the multi-population analysis (rs111490516), the two were in strong LD in the TOPMed
395	African population ( $R^2 = 1.00$ ). Both of these SNPs were fixed in the European group (MAF = 0%). In the
396	European group analysis, one SNP in the <i>ALKAL2</i> locus on chromosome 2 (rs62107261, $\beta$ = -0.102, SE =

397  $0.016, P = 2.08 \times 10^{-10}, MAF = 5\%$ ) was not in LD with the corresponding lead variant in the multi-398 population analysis (R<sup>2</sup> = 0.00, as calculated in the analysis subset), but was a known independent 399 secondary signal at this locus <sup>40</sup>. The remaining SNPs were in the proximity to the index SNPs in the 400 corresponding loci from the multi-population analysis.

401

# 402 **Replication**

403 The replication sample sizes ranged from 4,413 in BioMe to 79,889 in MVP (Supplementary
404 Data 7). In the five replication studies of Blacks, Africans, and African Americans, the MAF of

405 rs111490516 in MTMR3 ranged from 11% to 13%, aligning with the 13% observed in our African and

406 Barbadian groups and contrasting to the 0% to 5% range in our non-African discovery groups

407 (Supplementary Data 7). We replicated the novel variant rs111490516, demonstrating directionally

408 consistent associations with BMI across the replication studies and a 68% reduction in the estimated

409 effect when meta-analyzing across replication studies ( $\beta = 0.025$ , SE = 0.007,  $P = 4.76 \times 10^{-4}$ , MAF =

410 11%) compared to the discovery analysis (Figure 3, Supplementary Data 7). In the meta-analysis of

411 198,621 individuals from both discovery and replication studies, the estimated effect was 0.037 with a SE

412 of 0.006 and a *P*-value of  $4.19 \times 10^{-9}$  (Figure 3, Supplementary Data 7).

413 To gain a better understanding of the potential functional consequence of the *MTMR3* locus, we

414 used Ensembl VEP  $^{60}$  to annotate all variants in high LD with our top SNP ( $R^2 > 0.8$  in the African

415 population group using TOP-LD <sup>59</sup>). Of the 54 variants in high LD, most were intronic or nearby MTMR3

416 (Supplementary Data 8). Of these, four variants had a moderate CADD (combined annotation dependent

417 depletion) score (scaled CADD > 10) with rs73394881 having the highest relative CADD score<sup>61</sup>, three of

418 which lay within a possible enhancer (rs73396896,  $R^2 = 0.884$ ; rs73394881,  $R^2 = 0.889$ ; rs74832232,  $R^2 = 0.884$ ; rs73394881,  $R^2 = 0.889$ ; rs74832232,  $R^2 = 0.884$ ; rs73394881,  $R^2 = 0.889$ ; rs74832232,  $R^2 = 0.884$ ; rs73394881,  $R^2 = 0.889$ ; rs74832232,  $R^2 = 0.884$ ; rs73394881,  $R^2 = 0.889$ ; rs74832232,  $R^2 = 0.884$ ; rs73394881,  $R^2 = 0.889$ ; rs74832232,  $R^2 = 0.884$ ; rs73394881,  $R^2 = 0.889$ ; rs74832232,  $R^2 = 0.884$ ; rs73394881,  $R^2 = 0.889$ ; rs74832232,  $R^2 = 0.884$ ; rs73394881,  $R^2 = 0.889$ ; rs74832232,  $R^2 = 0.884$ ; rs73394881,  $R^2 = 0.889$ ; rs74832232,  $R^2 = 0.884$ ; rs73394881,  $R^2 = 0.889$ ; rs74832232,  $R^2 = 0.884$ ; rs748324, rs74832232, R^2 = 0.884; rs748324, rs7484, rs7484; rs7484, rs7484, rs7484, rs7484, rs7484; rs7484, r

419 0.889).

# 421 **Conditional Analyses**

422	Conditional analysis using the most associated variant at each locus revealed two significant
423	secondary signals after multiple testing correction (Tables 1, Supplementary Data 9, Supplementary
424	Figure 8). These included a known BMI-associated index variant on chromosome 2 (rs62107261, $\beta$ = -
425	0.097, SE = 0.014, $P = 2.06 \times 10^{-12}$ , near <i>ALKAL2</i> ) <sup>40</sup> , which was also the most significant variant at this
426	locus in the European group analysis (Supplementary Data 6). We further identified rs78769612 on
427	chromosome 18 ( $\beta$ = -0.100, SE = 0.019, $P = 2.17 \times 10^{-7}$ , near <i>MC4R</i> ). Although both secondary SNPs
428	were in known BMI-associated loci, rs78769612 near MC4R was a new index variant.
429	We additionally assessed independence for the top variants in known loci, by conditioning on all
430	previously-reported index variants <sup>5,29-48</sup> . Two SNPs, rs2206277 in <i>TFAP2B</i> and rs3838785 in <i>BDNF</i> ,
431	remained significant after multiple test correction, indicating potentially novel signals in known loci
432	(Supplementary Data 10). The novel index variant from the internal conditional analysis, rs78769612
433	near MC4R, was not robust to this treatment, suggesting that this novel variant was not independent of
434	known BMI variants. The LD matrix plots highlighted low LD ( $R^2$ range 0.018 – 0.342) between our top
435	SNP at the BDNF locus, rs3838785, and previously published lead variants within 500 kb
436	(Supplementary Fig. 9). Although our top SNP, rs2206277, in the TFAP2B locus was conditionally
437	independent of previously published BMI-risk SNPs ( $\beta \ge 90\%$ of the unconditioned $\beta$ and $P < 6.25 \times 10^{-10}$
438	<sup>3</sup> ), this SNP was in high LD with two nearby published SNPs ( $R^2 = 0.822$ for rs987237 and $R^2 = 0.793$ for
439	rs72892910).

440

# 441 Aggregate-based testing

We did not identify any novel gene regions through association tests at the genome-wide level (P443  $< 5 \times 10^{-7}$ ) when aggregating variants with MAF  $\leq 1\%$ . Nevertheless, we successfully replicated previous 444 gene-based associations with the well-known melanocortin 4 receptor (MC4R) gene ( $P = 8.47 \times 10^{-8}$ ), 445 with 111 alleles across 37 sites within coding regions, enhancers, and promoters for MC4R. The MC4R446 locus was also identified in single-variant analyses.

447

#### 448 **Fine-mapping**

To pinpoint the most probable causal variant(s) underlying each of the 16 loci, we subsequently 449 450 performed fine-mapping using PAINTOR<sup>53</sup>. Assuming one causal variant per locus, the index variants 451 were the most likely causal variants in 14 loci, with posterior probabilities (PP) ranging from 0.02 and 452 1.00, and seven of them had a PP above 0.50 (Supplementary Data 11, Supplementary Fig 10). Two intronic index variants, rs2307111 in POC5 and rs1379871 in DMD, were particularly noteworthy with 453 454 PP exceeding 0.98. In contrast, variants with the highest PP in ADCY3 and ZC3H4 were not the reported 455 index variants, although the highest PP for the ADCY3 locus was below 0.50, and thus not likely the 456 causal variant underlying this signal. In the ZC3H4 locus, the highest PP variant (rs55731973, PP = 0.77) 457 was intronic, located in the 5' UTR or upstream of ZC3H4 depending on alternative transcripts, and 458 resided in probable enhancer regions. Additionally, this variant was a significant cis-eQTL for SAE162, 459 another nearby downstream gene. 460 461 **PheWAS** To explore potential novel pleiotropy, we conducted association tests between the tag variant 462

464 PheCode was significantly associated with rs111490516 following multiple test correction ( $P < 9.3 \times 10^{-10}$ 

from our novel locus, rs111490516, and 538 PheCodes available in the MyCode and BioMe studies. No

<sup>5</sup>). However, PheCode 327.3 (Sleep Apnea) and 327.32 (Obstructive Sleep Apnea) ranked among the top

466 associated PheCodes (P < 0.001) (Supplementary Data 12, Supplementary Fig 11). Perhaps not

467 coincidentally, obesity is one of the strongest risk factors for sleep apnea  $^{63}$ .

468

463

#### 469 **DISCUSSION**

By leveraging WGS data from a large multi-population study, we identified and replicated one novel low-frequency BMI variant in *MTMR3*, specific to the diversity of our sample. We also identified two common secondary signals in known BMI loci, supported gene-based associations for *MC4R*, and

473 refined resolution in multiple loci by prioritizing candidate SNPs with high PP. Our discovery of the 474 novel BMI-associated variant emphasizes the importance of studying diverse populations, which could 475 further refine and expand the catalog of genes and variants that confer risk for obesity and potentially 476 other disease traits.

477 The novel MTMR3 variant, rs111490516, was most common in our African and Barbadian 478 population groups (MAF = 13%) and of moderate frequency in our Dominican population group (MAF = 479 5%). We further replicated this association in study samples of similar population background. Yet, 480 previous GWAS of BMI focusing on African ancestry individuals failed to identify a significant association in this region. It is not available for lookup in the most recent MVP BMI GWAS <sup>23</sup>, although 481 482 included in our replication. In one of the largest GWAS meta-analyses of imputed genotype data in 483 African ancestry individuals with summary data available publicly, which was conducted by the African Ancestry Anthropometry Genetics Consortium (AAAGC, N up to 42,751)<sup>37</sup>, this variant was directionally 484 consistent and suggestively associated ( $\beta = 0.042$ ,  $P = 1.80 \times 10^{-4}$ , MAF = 12%)<sup>37</sup>. Similarly, in our 485 486 replication analysis of 109,748 individuals with imputed genotypes, MTMR3 (rs111490516) was suggestively significant ( $\beta = 0.025$ ,  $P = 4.76 \times 10^{-4}$ , MAF = 11%). Therefore, the lack of discovery in 487 488 prior publications is likely not due to insufficient power. As indicated by our fine-mapping results for this 489 novel locus, our index SNP is likely not causal but could be in LD with a causal SNP and also poorly 490 captured in studies relying on imputation. In other words, the causal variant underlying this locus may be 491 nearby, less frequent, and on an LD block more frequent in a population poorly represented in other 492 imputation reference panels, but well represented in our WGS and highly diverse sample (e.g., Caribbean 493 admixed individuals). In this case, one would require sequencing data in a large sample size with the 494 relevant haplotype to detect a significant association that was not able to be identified with imputation in 495 a similar number of people.

The SNP rs111490516 lies in an intron of the *MTMR3* (myotubularin related protein 3) gene, with limited evidence of involvement in regulatory or functional protein activity. Other variants mapped to *MTMR3* have been associated with obesity-related traits in GWAS. In a study of 155,961 healthy and

medication-free UKBB participants, rs5752989 near MTMR3 was associated with fat-free mass ( $\beta =$ 

500	$0.115, P = 8.00 \times 10^{-9}$ , allele G frequency = 43%) <sup>64</sup> . In a meta-analysis of up to 628,000 BioBank Japan
501	(BBJ), UKBB, and FinnGen (FG) participants, the same SNP was associated with body weight ( $\beta$ = -
502	0.010, $P = 3.86 \times 10^{-8}$ , allele A frequency ranged from 51% in FG to 86% in BBJ) <sup>65</sup> .
503	The primary cellular function of MTMR3 relates to regulation of autophagy <sup>66</sup> . Although there is
504	no direct evidence linking MTMR3 to obesity, previous studies have established a connection between
505	<i>MTMR3</i> and related cardiometabolic traits. <i>MTMR3</i> was associated with LDL cholesterol ( $P = 1 \times 10^{-8}$ ) in
506	a GWAS meta-analysis of European, East Asian, South Asian, and African ancestry individuals <sup>67</sup> . A
507	potential mechanism was proposed later suggesting MTMR3 may mediate the association between
508	miRNA-4513 and total cholesterol <sup>68</sup> . Furthermore, pyruvate dehydrogenase complex-specific knockout
509	mice with high-fat diet induced obesity also exhibited increased blood glucose and higher expression
510	levels of MTMR3 <sup>69</sup> . We utilized the Ensembl VEP database to explore predicted functional consequences
511	of our novel locus. While there is limited knowledge on the biological implications of the lead variant and
512	those in high LD, there are multiple lines of evidence supporting a role in obesity at this locus.
513	The use of WGS coupled with inclusion of non-European populations improved fine-mapping
514	resolution, as has been shown previously <sup>47</sup> . While there have been multiple attempts to fine-map
515	previously identified BMI loci 5,33,48, no previous study has successfully identified BMI risk variants of
516	high confidence at the POC5 and DMD loci. By applying a Bayesian fine-mapping approach, we reduced
517	associated signals to 95% credible sets of two likely causal SNPs. Functional annotation revealed that one
518	of them, rs2307111, was a benign missense variant in POC5 (NP_001092741.1:p.His36Arg) according to
519	ClinVar <sup>70,71</sup> , while the other is an intron variant in the promotor region of <i>DMD</i> . These two variants were
520	also considered high-confidence causal variants ( $PP_{rs2307111} = 0.96$ , $PP_{rs1379871} = 0.99$ ) in a recent joint
521	analysis of three biobanks (UKBB, FG, BBJ) <sup>72</sup> . Notably, unlike in Kanai et al. where the PP appeared to
522	be driven by the Europeans (for rs2307111: $PP_{UKBB} = 0.96$ , $PP_{BBJ} = 0.12$ , $PP_{FG} = 0.01$ ; for rs1379871:

523  $PP_{UKBB} = 1.00$ ,  $PP_{FG} = 1.00$ ), the effect alleles in our study were observed in high proportions across many 524 non-European population groups (**Supplementary Data 5**).

In addition to our novel findings, 17 of the 18 identified variants reside in previously reported BMI-associated loci, highlighting the generalizability of the genes underlying BMI across populations, including *SEC16B*, *TMEM18*, *ETV5*, *GNPDA2*, *BDFN*, and *MC4R*  $^{5,34,48,73}$ . Three of the loci harbor genes implicated in severe and early-onset obesity – *ADCY3*, *BDNF*, and *MC4R*  $^{4}$ . We also consistently identified multiple association signals of high effect in *MC4R*, which is a well-established monogenic obesity gene, through our discovery analysis, internal conditional analysis, and rare variant aggregate analysis.

532 While our study included a large sample size of diverse populations and leveraged high quality 533 WGS data from well-characterized and harmonized cohorts, our results should also be interpreted with 534 the following limitations. First, although our study is large compared to other harmonized and sequenced 535 data samples, the total study size is relatively modest compared to existing GWAS meta-analyses of 536 common variants using imputed genotype data. Moreover, rare variants, such as those analyzed in our 537 study, may require even larger sample sizes for novel discoveries. Even though our study is among the 538 most racially, ethnically, and ancestrally diverse yet conducted, the European population group still 539 represented 49% of our participants. On the other hand, diversity can contribute to added heterogeneity of 540 effect sizes, potentially limiting discovery in the multi-population analysis. We sought to overcome this 541 limitation by allowing for heterogeneous residual variances across population groups and examining 542 population stratified results when samples sizes were adequate. Notably, all our genome-wide significant 543 loci from population stratified analyses were also captured in the multi-population analysis, likely owing 544 to our considerations of heterogenous effects, self-identity (population groups), and ancestry (genotype PCs). As has been shown by others <sup>47</sup>, this underscores the importance of conducting multi-population 545 analysis using appropriate methods that account for heterogeneity and minimize the risk of inflation or 546 547 missed detection of loci that may vary in MAF or phenotypic effects across populations.

548		In summary, our study demonstrates the power of leveraging WGS data from diverse populations				
549	for ne	for new discoveries associated with BMI. As we enter the era of incorporating GWAS-based risk models				
550	in clir	in clinical practice, it is critical that we continue to diversify the data collected and analyzed in genomic				
551	resear	ch. Failure to do so risks further exacerbating health disparities for public health crisis such as				
552	obesit	y. Ultimately, our study brings us one step closer to understanding the complex genetic				
553	under	pinnings of obesity, translating these leads into mechanistic insights, and developing targeted				
554	preve	ntions and interventions to address this global public health challenge.				
555						
556	DEFE	DENCEC				
557	KEFE	RENCES				
338						
559	1.	Collaborators, G.B.D.O. et al. Health Effects of Overweight and Obesity in 195 Countries over				
560		25 Years. N Engl J Med <b>377</b> , 13-27 (2017).				
561	2.	Chong, B. et al. Trends and predictions of malnutrition and obesity in 204 countries and				
562		territories: an analysis of the Global Burden of Disease Study 2019. EClinicalMedicine 57,				
563		101850 (2023).				
564	3.	Fatumo, S. et al. A roadmap to increase diversity in genomic studies. Nat Med 28, 243-250				
565		(2022).				
566	4.	Loos, R.J.F. & Yeo, G.S.H. The genetics of obesity: from discovery to biology. Nat Rev Genet				
567		<b>23</b> , 120-133 (2022).				
568	5.	Locke, A.E. et al. Genetic studies of body mass index yield new insights for obesity biology.				
569		<i>Nature</i> <b>518</b> , 197-206 (2015).				
570	6.	Speakman, J.R., Loos, R.J.F., O'Rahilly, S., Hirschhorn, J.N. & Allison, D.B. GWAS for BMI: a				
571		treasure trove of fundamental insights into the genetic basis of obesity. Int J Obes (Lond) 42,				
572		1524-1531 (2018).				

573	7.	Wainschtein, P. et al. Recovery of trait heritability from whole genome sequence data. bioRxiv,
574		588020 (2019).
575	8.	Taliun, D. et al. Sequencing of 53,831 diverse genomes from the NHLBI TOPMed Program.
576		<i>bioRxiv</i> , 563866 (2019).
577	9.	Abel, H.J. et al. Mapping and characterization of structural variation in 17,795 human genomes.
578		Nature 583, 83-89 (2020).
579	10.	Fang, H. et al. Harmonizing Genetic Ancestry and Self-identified Race/Ethnicity in Genome-
580		wide Association Studies. Am J Hum Genet 105, 763-772 (2019).
581	11.	Taliun, D. et al. Sequencing of 53,831 diverse genomes from the NHLBI TOPMed Program.
582		Nature <b>590</b> , 290-299 (2021).
583	12.	Regier, A.A. et al. Functional equivalence of genome sequencing analysis pipelines enables
584		harmonized variant calling across human genetics projects. Nat Commun 9, 4038 (2018).
585	13.	Jun, G., Wing, M.K., Abecasis, G.R. & Kang, H.M. An efficient and scalable analysis framework
586		for variant extraction and refinement from population-scale DNA sequence data. Genome Res 25,
587		918-25 (2015).
588	14.	Gogarten, S.M. et al. Genetic association testing using the GENESIS R/Bioconductor package.
589		Bioinformatics 35, 5346-5348 (2019).
590	15.	Brody, J.A. et al. Analysis commons, a team approach to discovery in a big-data environment for
591		genetic epidemiology. Nat Genet 49, 1560-1563 (2017).
592	16.	Sofer, T. et al. A fully adjusted two-stage procedure for rank-normalization in genetic association
593		studies. Genet Epidemiol 43, 263-275 (2019).
594	17.	Conomos, M.P., Miller, M.B. & Thornton, T.A. Robust inference of population structure for
595		ancestry prediction and correction of stratification in the presence of relatedness. Genet
596		<i>Epidemiol</i> <b>39</b> , 276-93 (2015).
597	18.	Conomos, M.P., Reiner, A.P., Weir, B.S. & Thornton, T.A. Model-free Estimation of Recent
598		Genetic Relatedness. Am J Hum Genet 98, 127-48 (2016).

- 599 19. Conomos, M.P. et al. Genetic Diversity and Association Studies in US Hispanic/Latino
- 600 Populations: Applications in the Hispanic Community Health Study/Study of Latinos. Am J Hum

601 *Genet* **98**, 165-84 (2016).

- Lin, D.Y. A simple and accurate method to determine genomewide significance for association
  tests in sequencing studies. *Genet Epidemiol* 43, 365-372 (2019).
- Kolonel, L.N. *et al.* A multiethnic cohort in Hawaii and Los Angeles: baseline characteristics. *Am J Epidemiol* 151, 346-57 (2000).
- 606 22. Gaziano, J.M. *et al.* Million Veteran Program: A mega-biobank to study genetic influences on
- 607 health and disease. *J Clin Epidemiol* **70**, 214-23 (2016).
- Huang, J. *et al.* Genomics and phenomics of body mass index reveals a complex disease network.
   *Nat Commun* 13, 7973 (2022).
- 610 24. Abul-Husn, N.S. *et al.* Implementing genomic screening in diverse populations. *Genome Med* 13,
  611 17 (2021).
- Sudlow, C. *et al.* UK biobank: an open access resource for identifying the causes of a wide range
  of complex diseases of middle and old age. *PLoS Med* 12, e1001779 (2015).
- 614 26. Bycroft, C. *et al.* The UK Biobank resource with deep phenotyping and genomic data. *Nature*615 562, 203-209 (2018).
- 616 27. Howard, V.J. *et al.* The reasons for geographic and racial differences in stroke study: objectives
  617 and design. *Neuroepidemiology* 25, 135-43 (2005).
- Willer, C.J., Li, Y. & Abecasis, G.R. METAL: fast and efficient meta-analysis of genomewide
  association scans. *Bioinformatics* 26, 2190-1 (2010).
- Wen, W. *et al.* Meta-analysis identifies common variants associated with body mass index in east
  Asians. *Nat Genet* 44, 307-11 (2012).
- 622 30. Okada, Y. *et al.* Common variants at CDKAL1 and KLF9 are associated with body mass index in
  623 east Asian populations. *Nat Genet* 44, 302-6 (2012).

624	31.	Berndt, S.I. et al. Genome-wide meta-analysis identifies 11 new loci for anthropometric traits and
625		provides insights into genetic architecture. Nat Genet 45, 501-12 (2013).

626 32. Monda, K.L. et al. A meta-analysis identifies new loci associated with body mass index in

627 individuals of African ancestry. *Nat Genet* **45**, 690-6 (2013).

- 628 33. Gong, J. *et al.* Fine Mapping and Identification of BMI Loci in African Americans. *Am J Hum*
- 629 *Genet* **93**, 661-71 (2013).
- 630 34. Wen, W. et al. Meta-analysis of genome-wide association studies in East Asian-ancestry

631 populations identifies four new loci for body mass index. *Hum Mol Genet* 23, 5492-504 (2014).

632 35. Winkler, T.W. *et al.* The Influence of Age and Sex on Genetic Associations with Adult Body Size

and Shape: A Large-Scale Genome-Wide Interaction Study. *PLoS Genet* 11, e1005378 (2015).

634 36. Fernandez-Rhodes, L. *et al.* Trans-ethnic fine-mapping of genetic loci for body mass index in the

- diverse ancestral populations of the Population Architecture using Genomics and Epidemiology
- 636 (PAGE) Study reveals evidence for multiple signals at established loci. *Hum Genet* **136**, 771-800
- 637 (2017).
- 638 37. Ng, M.C.Y. *et al.* Discovery and fine-mapping of adiposity loci using high density imputation of
- 639 genome-wide association studies in individuals of African ancestry: African Ancestry

640 Anthropometry Genetics Consortium. *PLoS Genet* **13**, e1006719 (2017).

- 38. Justice, A.E. *et al.* Genome-wide meta-analysis of 241,258 adults accounting for smoking
  behaviour identifies novel loci for obesity traits. *Nat Commun* 8, 14977 (2017).
- 643 39. Graff, M. et al. Genome-wide physical activity interactions in adiposity A meta-analysis of
- 644 200,452 adults. *PLoS Genet* **13**, e1006528 (2017).
- 40. Tachmazidou, I. *et al.* Whole-Genome Sequencing Coupled to Imputation Discovers Genetic
  Signals for Anthropometric Traits. *Am J Hum Genet* 100, 865-884 (2017).
- 647 41. Akiyama, M. *et al.* Genome-wide association study identifies 112 new loci for body mass index
  648 in the Japanese population. *Nat Genet* 49, 1458-1467 (2017).

649	42.	Turcot, V. et al. Protein-altering variants associated with body mass index implicate pathways
650		that control energy intake and expenditure in obesity. Nat Genet 50, 26-41 (2018).

- 43. Gong, J. et al. Trans-ethnic analysis of metabochip data identifies two new loci associated with
- 652 BMI. Int J Obes (Lond) 42, 384-390 (2018).
- 44. Hoffmann, T.J. *et al.* A Large Multiethnic Genome-Wide Association Study of Adult Body Mass
  Index Identifies Novel Loci. *Genetics* 210, 499-515 (2018).
- 45. Yengo, L. et al. Meta-analysis of genome-wide association studies for height and body mass
- 656 index in approximately 700000 individuals of European ancestry. *Hum Mol Genet* **27**, 3641-3649
- 657 (2018).

46. Kichaev, G. *et al.* Leveraging Polygenic Functional Enrichment to Improve GWAS Power. *Am J Hum Genet* 104, 65-75 (2019).

- 47. Wojcik, G.L. *et al.* Genetic analyses of diverse populations improves discovery for complex
  traits. *Nature* 570, 514-518 (2019).
- 48. Fernandez-Rhodes, L. et al. Ancestral diversity improves discovery and fine-mapping of genetic
- loci for anthropometric traits-The Hispanic/Latino Anthropometry Consortium. *HGG Adv* 3,
  100099 (2022).
- 49. Machiela, M.J. & Chanock, S.J. LDlink: a web-based application for exploring populationspecific haplotype structure and linking correlated alleles of possible functional variants.
- 667 *Bioinformatics* **31**, 3555-7 (2015).
- 668 50. Consortium, F. et al. A promoter-level mammalian expression atlas. Nature 507, 462-70 (2014).
- 51. Fishilevich, S. *et al.* GeneHancer: genome-wide integration of enhancers and target genes in
  GeneCards. *Database (Oxford)* 2017(2017).
- 671 52. Chen, H. *et al.* Efficient Variant Set Mixed Model Association Tests for Continuous and Binary
  672 Traits in Large-Scale Whole-Genome Sequencing Studies. *Am J Hum Genet* 104, 260-274
- 673 (2019).

- 53. Kichaev, G. et al. Integrating functional data to prioritize causal variants in statistical fine-
- 675 mapping studies. *PLoS Genet* **10**, e1004722 (2014).
- 676 54. Carey, D.J. et al. The Geisinger MyCode community health initiative: an electronic health record-
- 677 linked biobank for precision medicine research. *Genet Med* **18**, 906-13 (2016).
- 678 55. Abul-Husn, N.S. & Kenny, E.E. Personalized Medicine and the Power of Electronic Health
- 679 Records. *Cell* **177**, 58-69 (2019).
- 56. Wu, P. *et al.* Mapping ICD-10 and ICD-10-CM Codes to Phecodes: Workflow Development and
  Initial Evaluation. *JMIR Med Inform* 7, e14325 (2019).
- 682 57. Carroll, R.J., Bastarache, L. & Denny, J.C. R PheWAS: data analysis and plotting tools for
- 683 phenome-wide association studies in the R environment. *Bioinformatics* **30**, 2375-6 (2014).
- 58. Dewey, F.E. *et al.* Distribution and clinical impact of functional variants in 50,726 whole-exome
  sequences from the DiscovEHR study. *Science* 354(2016).
- 59. Huang, L. *et al.* TOP-LD: A tool to explore linkage disequilibrium with TOPMed whole-genome
  sequence data. *Am J Hum Genet* 109, 1175-1181 (2022).
- 688 60. McLaren, W. et al. The Ensembl Variant Effect Predictor. Genome Biol 17, 122 (2016).
- 689 61. Kircher, M. *et al.* A general framework for estimating the relative pathogenicity of human genetic
  690 variants. *Nat Genet* 46, 310-5 (2014).
- 691 62. Consortium, G.T. The Genotype-Tissue Expression (GTEx) project. *Nat Genet* 45, 580-5 (2013).
- 692 63. Jehan, S. *et al.* Obstructive Sleep Apnea and Obesity: Implications for Public Health. *Sleep Med* 693 *Disord* 1(2017).
- 694 64. Hubel, C. *et al.* Genomics of body fat percentage may contribute to sex bias in anorexia nervosa.
  695 *Am J Med Genet B Neuropsychiatr Genet* 180, 428-438 (2019).
- 696 65. Sakaue, S. *et al.* A cross-population atlas of genetic associations for 220 human phenotypes. *Nat*697 *Genet* 53, 1415-1424 (2021).
- 698 66. Vergne, I. & Deretic, V. The role of PI3P phosphatases in the regulation of autophagy. *FEBS Lett*699 584, 1313-8 (2010).

- 700 67. Willer, C.J. et al. Discovery and refinement of loci associated with lipid levels. Nat Genet 45,
- 701 1274-1283 (2013).
- 68. Ghanbari, M. et al. A genetic variant in the seed region of miR-4513 shows pleiotropic effects on
- 103 lipid and glucose homeostasis, blood pressure, and coronary artery disease. *Hum Mutat* **35**, 1524-
- 704 31 (2014).
- 69. Geng, Z. *et al.* RNA-Seq analysis of obese Pdha1(fl/fl)Lyz2-Cre mice induced by a high-fat diet.
- 706 *Exp Anim* (2022).
- 707 70. Landrum, M.J. et al. ClinVar: improving access to variant interpretations and supporting
- 708 evidence. *Nucleic Acids Res* **46**, D1062-D1067 (2018).
- 709 71. ClinVar, N.C.f.B.I. VCV001233562.6.
- 710 72. Kanai, M. et al. Insights from complex trait fine-mapping across diverse populations. medRxiv,
- 711 2021.09.03.21262975 (2021).
- 712 73. Hotta, K. et al. Association between obesity and polymorphisms in SEC16B, TMEM18,
- 713 GNPDA2, BDNF, FAIM2 and MC4R in a Japanese population. *J Hum Genet* **54**, 727-31 (2009).
- 714
- 715

716

717

718 719

720

# TABLES

CHR	POS (hg38)	Nearest gene	rsID	REF	ALT	ALT Freq	Beta	SE	<i>P</i> -value	Known index variant <sup>a</sup>	Novel Locus <sup>b</sup>				
	Top variant in each locus														
1	177920345	SEC16B	rs543874	А	G	20%	0.064	0.006	1.38E-26	Yes	No				
2	621558	TMEM18	rs939584	С	Т	85%	0.058	0.007	1.99E-17	No	No				
2	24927427	ADCY3	rs10182181	А	G	56%	0.035	0.005	1.76E-11	Yes	No				
3	186108951	ETV5	rs869400	Т	G	82%	0.038	0.006	1.21E-09	No	No				
4	45179317	GNPDA2	rs12507026	А	Т	36%	0.045	0.005	9.55E-19	Yes	No				
5	75707853	POC5	rs2307111	Т	С	55%	-0.032	0.005	7.43E-10	Yes	No				
6	50830813	TFAP2B	rs2206277	С	Т	19%	0.054	0.006	2.05E-18	Novel	No				
8	76068626	HNF4G	rs830463	А	G	47%	0.031	0.005	6.58E-10	No	No				
11	27657463	BDNF	rs3838785	GT	G	58%	-0.030	0.005	3.14E-09	Novel	No				
12	49853685	BCDIN3D	rs7138803	G	А	30%	0.036	0.005	1.69E-11	Yes	No				
13	53533448	OLFM4	rs9568868	G	Т	14%	0.047	0.007	5.73E-11	No	No				
16	53767042	FTO	rs1421085	Т	С	29%	0.090	0.006	6.11E-59	Yes	No				
18	60161902	MC4R	rs6567160	Т	С	21%	0.053	0.006	8.22E-19	Yes	No				
19	47077985	ZC3H4	rs28590228	С	Т	50%	0.033	0.005	4.75E-10	No	No				
22	29906934	MTMR3	rs111490516	С	Т	4%	0.078	0.013	4.52E-09	Novel	Yes				
Х	31836665	DMD	rs1379871	G	С	41%	0.029	0.004	1.35E-11	Yes	No				
	Secondary signals														
2	422144	ALKAL2	rs62107261	Т	С	3%	-0.095	0.014	3.83E-12	Yes	No				
18	60361739	MC4R	rs78769612	G	Т	2%	-0.106	0.019	3.53E-08	No	No				

Table 1. Summary of independent loci reaching genome-wide significance ( $P < 5 \times 10^{-9}$ ) in single variant and internal conditional analyses

Newly identified locus highlighted in bold. CHR, chromosome; POS, position; REF, reference allele; ALT, alternative allele; ALT Freq, alternative allele frequency; SE, standard error.

<sup>a</sup> Known index variant 'Yes' indicates previously published index variant from NHGRI-EBI GWAS Catalog; 'No' indicates index variant within 500 kb  $\pm$  of the published lead variant, not independent of known signal in conditional analysis; 'Novel' indicates new lead variant either not published or conditionally independent.

<sup>b</sup> Novel locus 'Yes' was defined if there is no known index variant within 500 kb  $\pm$  of the lead variant in current analysis.

# FIGURES

#### Figure 1. Study population group composition.

A) Pairwise scatter plots of the first three principal components (PCs) by population group. B) This image contains a lollipop chart and a waffle plot illustrating the number and proportion of participants by population group. Our study population was composed of 88,873 participants from 15 population groups, 51% of which are non-European.



# Figure 2. Summary of significant association findings.

A) Manhattan plot of multi-population, single variant analysis (N = 88,873 individuals). The novel locus (*MTMR3*) is highlighted in red. Previously reported BMI loci are in dark beige. The horizontal dashed line indicates genome-wide significance threshold  $P = 5 \times 10^{-9}$ . B) Scatterplot showing the minor allele frequency compared to the absolute value of the estimate effect of the index variant at each significant locus. All effect estimates are from the primary analysis conducted across all population groups. Previously reported loci are highlighted in blue, while the novel locus is in red; circles represent the most significant variant at each locus, and triangles show newly reported secondary signals within known loci.



**Figure 3. Forest plot of rs111490516 replication.** All effect estimates (95% confidence interval) are oriented on the BMI increasing allele and are provided as standard deviation per allele. Actual beta values and *P*-values are in Supplementary Data 7.



Forest Plot of Meta-Analysis of rs111490516 in MTMR3